Skip to main content

Table 3 Factors associated with serious adverse events determined by univariate and multivariate mixed-effects model analysis

From: Decreasing severe pain and serious adverse events while moving intensive care unit patients: a prospective interventional study (the NURSE-DO project)

  Univariate analysis Multivariate analysis
  All procedures
( n = 632)
Serious adverse events
YES
( n = 164)
Serious adverse events
NO
( n = 468)
P OR
(95% CI)
P
Phase 1, n (%) 184 (29%) 68 (41%) 116 (25%)    
Phase 2, n (%) 129 (20%) 36 (22%) 93 (20%) 0.09   
Phase 3, n (%) 170 (27%) 29 (18%) 141 (30%) < 0.001 0.40 (0.23; 0.72) < 0.01
Phase 4, n (%) 149 (24%) 31 (19%) 118 (25%) < 0.01 0.53 (0.30; 0.92) 0.03
Age, median (IQR) 63 (51; 71) 64 (56; 75) 62 (51; 70) 0.09   
Female gender, n (%) 186 (29%) 44 (27%) 142 (30%) 0.44   
SAPS II, median (IQR) 39 (29; 41) 39 (31; 53) 38 (28; 50) 0.19   
Surgical admission, n (%) 219 (35%) 104 (63%) 309 (66%) 0.54   
Intubation status, n (%) 216 (34%) 79 (48%) 137 (29%) < 0.01 1.91 (1.28; 2.85) < 0.01
Sustained use of sedatives, n (%) 114 (18%) 38 (23%) 76 (16%) 0.17   
RASS level, median (IQR) 0 (-1; 0) 0 (-2; 0) 0 (-1; 0) 0.05   
Pain during moving       
Moderate pain, n (%) 160 (25%) 41 (25%) 119 (25%) 0.81   
Severe pain, n (%) 61 (10%) 30 (18%) 31 (7%) < 0.001 2.74 (1.54; 4.89) < 0.001
  1. CI, Confidence interval; IQR, Interquartile Range (25th to 75th percentiles); OR, Odds ratio; RASS, Richmond Agitation-Sedation Scale [29]; SAPS II, Simplified Acute Physiology Score II [31]. In addition to studied phases, variables were selected in multivariate-analysis if P-value was less than 0.20 in the univariate analysis, that is, were included in the final mixed-effect model: studied phases, age, SAPS II, intubation status, sustained use of sedatives, RASS level and severe-pain events.